

Prolidase deficiency

Author: Professor Jaak Jaeken¹

Creation Date: August 2001

Update: January 2004

Scientific Editor: Professor Jean-Marie Saudubray

¹Center for Metabolic Disease, University Hospital Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium.
jaak.jaeken@uz.kuleuven.ac.be

[Abstract](#)

[Keywords](#)

[Disease name](#)

[Excluded diseases](#)

[Diagnostic criterium](#)

[Differential diagnosis](#)

[Prevalence](#)

[Clinical description](#)

[Management](#)

[Etiology](#)

[Diagnostic methods](#)

[Genetic counseling](#)

[Antenatal diagnosis](#)

[Unresolved questions](#)

[References](#)

Abstract

Prolidase deficiency is a very rare autosomal recessive disease. Prevalence remains unknown, some 40 cases have been reported. It is characterized by mild to severe skin lesions particularly on the face, palms, lower legs and soles, besides variable other features. Patients excrete massive amounts of iminodipeptides in urine due to a deficiency of the exopeptidase prolidase. The activity of this enzyme can be measured in hemolysates, leukocytes or fibroblasts. Mutations in the PEPD gene on chromosome 19p13.2 have been observed. The skin ulcers respond partially to local treatment.

Keywords

prolidase, iminodipeptiduria

Disease name

Prolidase deficiency

Excluded diseases

Lathyrism

Diagnostic criterium

Prolidase deficiency

Differential diagnosis

Systemic lupus erythematosus

Prevalence

Unknown; some 40 individuals have been reported.

Clinical description

First symptoms start between birth and young adult age. Most characteristic are the skin lesions ranging from mild to severe, including recalcitrant ulcerations. They are mostly located on the face, the palms, the lower legs and the soles. Other features are facial dysmorphism, psychomotor retardation and recurrent infections.

Management

This is limited to treatment of the skin ulcers with oral ascorbate, manganese (cofactor of prolidase), inhibitors of collagenase, and local

applications of L-proline-and glycine-containing ointments. Response to treatment is variable.

Etiology

Mutations in the *PEPD* gene on chromosome 19p13.2.

Diagnostic methods

- Partition and elution chromatography,
- direct chemical ionisation mass spectrometry,
- enzymatic test.

Genetic counseling

Autosomal recessive inheritance.

Antenatal diagnosis

It is possible on amniocytes and chorionic villi.

Unresolved questions

An efficient treatment is not available.

References

Goodman SI, Solomons CC, Muschenheim F *et al.* (1968) A syndrome resembling lathyrism associated with iminodipeptiduria. *Am J Med* 45:152-159

Jemec GB, Moe AT (1996) Topical treatment of skin ulcers in prolidase deficiency. *Pediatr Dermatol* 13:58-60

Ledoux P, Scriver CR, Hechtman P (1996) Expression and molecular analysis of mutations in prolidase deficiency. *Am J Hum Genet* 59:1035-1039

Shrinath M, Walter JH, Haeney M *et al.* (1997) Prolidase deficiency and systemic lupus erythematosus. *Arch Dis Child* 76:441-444